Intellectual Property
VaxDesign owns or has exclusively licensed twelve pending United States patent applications claiming the MIMIC™ technology. We have filed or plan to file foreign counterparts to our U.S. applications in major market countries.
Published Patents and Patent Applications
Artificial immune system: methods for making and use.
US 2005 / 0282148, also published as WO 2005 / 104755.
Warren, Fahlenkamp, Higbee, Kachurin, Li, Nguyen, Parkhill, Sanchez-Schmitz, Irvine, Randolph, Hacohen, TorbettAutomatable artificial immune system (AIS).
US 2006 / 0270029.
Warren, Parkhill, Nguyen, Sanchez-Schmitz, Fahlenkamp, Higbee, Drake, Kachurin, MoeAutomatable artificial immune system (AIS).
US 2007 / 0141552.
Parkhill, Nguyen, Sanchez-Schmitz, Fahlenkamp, Higbee, Drake, Kachurin, Moe, WarrenIn vitro mucosal tissue equivalent.
US 2006 / 0275270, also published as WO 2007 / 106559.
Sanchez-Schmitz, Higbee, Fahlenkamp, Warren, Drake, TewDisease Model Incorporation into an Artificial Immune System (AIS).
US 2007 / 0026392, also published as WO 2007 / 0144267.
Higbee, Mishkin, Warren, Sanchez-Schmitz, Fahlenkamp, RivardControlling dendritic cell maturation state in the lymphoid tissue equivalent of an artificial immune system.
US 2007 / 0015136
Sanchez-Schmitz, Higbee, Fahlenkamp, Irvine, Warren, DrakeA porous membrane device that promotes differentiation of monocytes into dendritic cells.
WO 2007 / 076061, also published as US 2007 / 0178076
Drake, Moe, Li, Fahlenkamp, Sanchez-Schmitz, Higbee, Parkhill, WarrenIn vitro germinal centers.
WO 2007 / 075979, also published as US 2007 / 0218054
Sukumar, El Shikh, Tew, Sanchez-Schmitz, Drake, Mosquera, Li, Kachurin, Higbee, Fahlenkamp, WarrenCo-Culture Lymphoid Tissue Equivalent (LTE) for an Artificial Immune System (AIS).
US 2007 / 0154956, also published as WO 2007 / 146334.
Drake, Moser, Singh, Song, Mishkin, WarrenModels for vaccine assessment.
US 2008 / 0008653.
Tew, El Shikh, Singh, Mishkin, Drake, Song, Warren
Foreign Filings
We have filed US and PCT applications and national phase applications in the major markets, typically the European Patent Office, Japan, Australia, and Canada. We file in other countries on a case-by-case basis.